Loading clinical trials...

Evaluating the Diagnostic and Predictive Value of Non-invasive Tests (NITs) on the Progression of Chronic Liver Disease. | Clinical Trials | Clareo Health

NOT_YET_RECRUITING

Evaluating the Diagnostic and Predictive Value of Non-invasive Tests (NITs) on the Progression of Chronic Liver Disease.

NCT05312853•Johannes Gutenberg University Mainz

View on ClinicalTrials.gov

Summary

Primary objective is to study the relevance of non-invasive test (NITs) in predicting disease stage (diagnostic biomarker) and outcome (predictive biomarker) in patients with suspected or established liver disease and cirrhosis.

Detailed Description

Non-invasive tests (NITs) may complement and even reduce the need for liver biopsy in the diagnosis and follow up care of patients with chronic liver disease (CLD). NITs either include serum biomarkers (direct or indirect) or ultrasound-based tests, including vibration controlled transient elastography (VCTE), or a combination of both incorporated into several surrogate scores.

Eligibility

Age

18 - 99 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Age ≥18 years
•2. Clinically suspected chronic liver disease based on any of:
•1. Patient with historical liver biopsy providing histological evidence of any liver disease or,
•2. Patient undergoing liver biopsy for suspected chronic liver disease with biochemical and/or radiological findings consistent with liver disease or,
•3. Patient with clinical and radiological evidence of cirrhosis (in absence of an alternative aetiology)
•4. Patients with metabolic risk factors predisposing to CLD

Exclusion Criteria

•1. Refusal or inability (lack of capacity) to give informed consent.
•2. Age \< 18 years
•3. Pregnancy
•4. An active malignancy.
•5. Life expectation of \< 5 years.

Locations (1)

University Medical Center of the Johannes Gutenber Univeristy

Mainz, Germany

Key Dates

Start Date

January 15, 2024

Primary Completion Date

April 15, 2034

Completion Date

December 31, 2034

Last Updated

January 3, 2024

Enrollment

250

ESTIMATED participants

Conditions

Chronic Liver Disease

Contacts

Joern Schattenberg, Prof. Dr.

CONTACT

+49 (0) 6131 17 joern.schattenberg@unimedizin-mainz.de

Belinda Schröder, MSc

CONTACT

+49 (0) 6131 17 belinda.schroeder@unimedizin-mainz.de

Assessment of Changes in Bone Mineral Metabolism After Liver Transplantation by Bone Mineral Densitometry

NCT07480057

Chronic Liver Disease and ACLF

View study

RECRUITING

LSM and SSM for the Diagnosis of CSPH: a Prospective Cohort Study

NCT06181409

Advanced Chronic Liver Disease

View study

RECRUITINGPHASE4

Non-selective Beta-blocker in Compensated Advanced Chronic Liver Disease

NCT06449339

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 3, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Evaluating the Diagnostic and Predictive Value of Non-invasive Tests (NITs) on the Progression of Chronic Liver Disease.

Inclusion Criteria

Exclusion Criteria

Assessment of Changes in Bone Mineral Metabolism After Liver Transplantation by Bone Mineral Densitometry

LSM and SSM for the Diagnosis of CSPH: a Prospective Cohort Study

Non-selective Beta-blocker in Compensated Advanced Chronic Liver Disease

Albumin Modifications as Early Biomarkers of Chronic Liver Diseases

Non-invasive Methods for Predicting Decompensation of Chronic Liver Disease

VIATORR Device Registry